Turkish translation, validity, and reliability of the European organization for research and treatment of cancer quality of life-high dose chemotherapy29 in patients undergone hematopoietic stem cell transplantation

欧洲癌症研究与治疗组织生活质量-高剂量化疗29在接受造血干细胞移植患者中的土耳其语翻译、有效性和可靠性

阅读:1

Abstract

BACKGROUND/AIM: Our aim was to investigate psychometric properties of the Turkish version of the European organization for research and treatment of cancer quality of life-high dose chemotherapy29 (EORTC QLQ-HDC29) in patients treated with hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Patients between the ages of 18 and 65 years and undergone HSCT were included. The European organization for research and treatment of cancer quality of life questionnaire-cancer30 the Eastern cooperative oncology group performance score, and the functional assessment of cancer therapy-bone marrow transplant were used to determine convergent validity. Reliability was assessed through the calculation of Cronbach's alpha and intra-class correlation coefficient (ICC) values. RESULTS: Totally 151 patients were included. The convergent validity analysis between the EORTC QLQ-HDC29 and the other variables revealed significant, low to strong correlations (p < 0.05). The test-retest reliability of the questionnaire was excellent (ICC values ranged from 0.886 to 1.000). The internal consistency values were acceptable except for the "Worries/Anxiety" and "Inpatient Issues" scales (ranged from 0.175 to 0.985). CONCLUSION: The reliability and validity of Turkish version of the EORTC QLQ-HDC29 was feasible and acceptable in patients treated with HSCT. Further research is required to ascertain the psychometric properties of the EORTC QLQ-HD29.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。